March 13, 2023 — 08:18 am EDT

      Written by
                        RTTNews.com for                             
        




RTTNews ->


(RTTNews) - Mersana Therapeutics, Inc. (MRSN) announced the Phase 1 trial of XMT-2056 has been placed on clinical hold by the FDA. This FDA action follows the company's communication to FDA that Mersana was voluntarily suspending the trial due to a recent fatal serious adverse event that was deemed to be related to XMT-2056. 
"With the clinical hold in place, our efforts for XMT-2056 are now focused on undertaking the work required to fully analyze this SAE and consider potential next steps for development," said Anna Protopapas, CEO of Mersana Therapeutics.
Shares of Mersana Therapeutics are down 17% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com. 
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

© 2023, Nasdaq, Inc. All Rights Reserved.










To add symbols:


These symbols will be available throughout the site during your session.
To add symbols:


These symbols will be available throughout the site during your session.